These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

649 related articles for article (PubMed ID: 37841212)

  • 1. Comparison of the profiles of first-line PD-1/PD-L1 inhibitors for advanced NSCLC lacking driver gene mutations: a systematic review and Bayesian network meta-analysis.
    Wenfan F; Manman X; Xingyuan S; Zeyong J; Jian Z; Lu D
    Ther Adv Chronic Dis; 2023; 14():20406223231189224. PubMed ID: 37841212
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of immune checkpoint inhibitors for advanced non-small cell lung cancer with or without PD-L1 selection: A systematic review and network meta-analysis.
    Li Y; Liang X; Li H; Chen X
    Chin Med J (Engl); 2023 Sep; 136(18):2156-2165. PubMed ID: 37596898
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of first-line immunotherapies for advanced non-small cell lung cancer.
    Yang SC; Ou HT; Su WC; Wang SY
    Cancer Med; 2023 Apr; 12(7):8838-8850. PubMed ID: 36653947
    [TBL] [Abstract][Full Text] [Related]  

  • 4. First-line treatment options for advanced non-small cell lung cancer patients with PD-L1 ≥ 50%: a systematic review and network meta-analysis.
    He M; Zheng T; Zhang X; Peng Y; Jiang X; Huang Y; Tan B; Yang Z
    Cancer Immunol Immunother; 2022 Jun; 71(6):1345-1355. PubMed ID: 34657171
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
    Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
    Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
    Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and Safety of First-Line Immunotherapy Combinations for Advanced NSCLC: A Systematic Review and Network Meta-Analysis.
    Liu L; Bai H; Wang C; Seery S; Wang Z; Duan J; Li S; Xue P; Wang G; Sun Y; Du X; Zhang X; Ma Z; Wang J
    J Thorac Oncol; 2021 Jul; 16(7):1099-1117. PubMed ID: 33839365
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Feasibility and safety of PD-1/L1 inhibitors for non-small cell lung cancer in front-line treatment: a Bayesian network meta-analysis.
    Liang H; Lin G; Wang W; Huang J; Yang Y; Lan Y; Wang R; Cui F; Hao Z; Deng H; Zhao S; Cheng B; Xiong S; Li J; Li C; Liu J; He J; Liang W
    Transl Lung Cancer Res; 2020 Apr; 9(2):188-203. PubMed ID: 32420059
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of first-line checkpoint inhibitors-based treatments for non-oncogene-addicted non-small-cell lung cancer: a systematic review and meta-analysis.
    Siciliano MA; Caridà G; Ciliberto D; d'Apolito M; Pelaia C; Caracciolo D; Riillo C; Correale P; Galvano A; Russo A; Barbieri V; Tassone P; Tagliaferri P
    ESMO Open; 2022 Jun; 7(3):100465. PubMed ID: 35427835
    [TBL] [Abstract][Full Text] [Related]  

  • 10. First-line PD-1/PD-L1 inhibitors plus chemotherapy versus bevacizumab plus chemotherapy for advanced non-squamous non-small cell lung cancer: A Bayesian network meta-analysis of randomized controlled trials.
    Zhai J; Lu J; Zhang Z; Wang Y; Li X; Zhang S; Mu S; Zhi X; Ge X; Lu D; Hu Y; Wang J
    Cancer Med; 2022 May; 11(10):2043-2055. PubMed ID: 35315579
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A systematic review and network meta-analysis of first-line immune checkpoint inhibitor combination therapies in patients with advanced non-squamous non-small cell lung cancer.
    Shao T; Zhao M; Liang L; Tang W
    Front Immunol; 2022; 13():948597. PubMed ID: 36389713
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selection of optimal first-line immuno-related therapy based on specific pathological characteristics for patients with advanced driver-gene wild-type non-small cell lung cancer: a systematic review and network meta-analysis.
    Sheng L; Gao J; Xu Q; Zhang X; Huang M; Dai X; Li S; Liu L
    Ther Adv Med Oncol; 2021; 13():17588359211018537. PubMed ID: 34104227
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Network Meta-Analysis of Cancer Immunotherapies
    Herbst R; Jassem J; Abogunrin S; James D; McCool R; Belleli R; Giaccone G; De Marinis F
    Front Oncol; 2021; 11():676732. PubMed ID: 34307144
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identifying optimal first-line immune checkpoint inhibitors based regiments for advanced non-small cell lung cancer without oncogenic driver mutations: A systematic review and network meta-analysis.
    Liu T; Wu S; Fang W; Li H; Su L; Qi G; Li H; Liu Y
    PLoS One; 2023; 18(4):e0283719. PubMed ID: 37071610
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of antiangiogenic agents in first-line treatment for advanced NSCLC in the era of immunotherapy.
    Pang LL; Gan JD; Huang YH; Liao J; Zhuang WT; Ali WA; Hong SD; Zhang L; Fang WF
    BMC Cancer; 2023 Jan; 23(1):72. PubMed ID: 36670414
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of Efficacy and Safety of Single and Double Immune Checkpoint Inhibitor-Based First-Line Treatments for Advanced Driver-Gene Wild-Type Non-Small Cell Lung Cancer: A Systematic Review and Network Meta-Analysis.
    Xu Q; Zhang X; Huang M; Dai X; Gao J; Li S; Sheng L; Huang K; Wang J; Liu L
    Front Immunol; 2021; 12():731546. PubMed ID: 34484242
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PD-1/PD-L1 inhibitor plus chemotherapy versus bevacizumab plus chemotherapy in first-line treatment for non-squamous non-small-cell lung cancer.
    Yu H; Chen P; Xia L; Fu S; Chen C; Zhang X; He L; Zhang B; Zhou Y; Hong S
    J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34750245
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term comparative efficacy and safety of nivolumab plus ipilimumab relative to other first-line therapies for advanced non-small-cell lung cancer: A systematic literature review and network meta-analysis.
    O'Byrne K; Popoff E; Badin F; Lee A; Yuan Y; Lozano-Ortega G; Eccles LJ; Varol N; Waser N; Penrod JR; Goring S
    Lung Cancer; 2023 Mar; 177():11-20. PubMed ID: 36669321
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The impact of PD-L1 on survival and value of the immune check point inhibitors in non-small-cell lung cancer; proposal, policies and perspective.
    Guirgis HM
    J Immunother Cancer; 2018 Feb; 6(1):15. PubMed ID: 29463302
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the efficacy and safety in the treatment strategies between chemotherapy combined with antiangiogenic and with immune checkpoint inhibitors in advanced non-small cell lung cancer patients with negative PD-L1 expression: A network meta-analysis.
    Li J; Chen Y; Hu F; Qiang H; Chang Q; Qian J; Shen Y; Cai Y; Chu T
    Front Oncol; 2022; 12():1001503. PubMed ID: 36523992
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.